CD44

CD44 antigen · P16070 · CD44 on Sugi Atlas →

5,650 patent compounds predicted against CD44, 3,540 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL19085)	1.00	2/20
SCHEMBL329571	1.00	2/20
SCHEMBL2808722	1.00	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL987515)	0.95	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL1600927)	0.95	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL2082936)	0.95	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL3249720)	0.79	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL440578)	0.76	2/20
SCHEMBL509247	0.75	2/20
SCHEMBL233066	0.74	2/20
SCHEMBL2116528	0.73	2/20
SCHEMBL3610631	0.73	2/20
SCHEMBL3659651	0.72	2/20
Hydrochloric Acid (SCHEMBL2876610)	0.71	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL2084611)	0.70	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL2084613)	0.70	2/20
SCHEMBL329619	0.68	2/20
1,2,3,4-Tetrahydroisoquinoline (SCHEMBL1747872)	0.68	2/20
SCHEMBL327075	0.61	2/20
SCHEMBL1010522	0.61	2/20

Clinical trials — most relevant to CD44 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation	PHASE3	COMPLETED
4SCAR-CD44v6 T Cell Therapy Targeting Cancer	PHASE1/PHASE2	RECRUITING
Multi-4SCAR-T Therapy Targeting Breast Cancer	PHASE1/PHASE2	RECRUITING
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer	PHASE2	COMPLETED
Autogenous Mesenchymal Stem Cell Culture-Derived Signalling Molecules as Enhancers of Bone Formation in Bone Grafting	PHASE1/PHASE2	NOT_YET_RECRUITING
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients	PHASE2	UNKNOWN
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer	PHASE2	COMPLETED
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.	PHASE2	WITHDRAWN
Quantitating the Impact of Plerixafor	PHASE1/PHASE2	UNKNOWN
NG2 and DLL3 CAR-T Cells Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Effect of Mesenchymal Stromal Cells on Sepsis and Septic Shock	PHASE1/PHASE2	COMPLETED
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	PHASE2	RECRUITING
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme	PHASE1	ENROLLING_BY_INVITATION
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation	PHASE1	WITHDRAWN
Methylation Status of CD44 Promoter Region in Primary Lung Cancer	nan	UNKNOWN
Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis	nan	UNKNOWN
Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma	nan	NOT_YET_RECRUITING
Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer	nan	WITHDRAWN
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients	nan	COMPLETED
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer	nan	COMPLETED
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer	nan	WITHDRAWN
CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer	nan	RECRUITING
Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus	nan	COMPLETED
Characterization of Ovarian Cancer Stem Cell	nan	UNKNOWN
Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area	nan	UNKNOWN
Perioperative Plasma Levels of Glycocalyx Markers in Colon Surgery.	nan	UNKNOWN
Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia	nan	NOT_YET_RECRUITING
Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma	nan	UNKNOWN
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CD44 binder may also engage these)

Protein	Name	Similarity
P15379	—	0.995	P15379 →
P26051	—	0.988	P26051 →
Q8C6Z1	—	0.974	Q8C6Z1 →
Q8MI01	—	0.969	Q8MI01 →
Q8CAE9	—	0.965	Q8CAE9 →
A1XQY0	—	0.964	A1XQY0 →
Q4W8E7	—	0.962	Q4W8E7 →
Q8N387	—	0.962	Q8N387 →
Q9HDB5	—	0.961	Q9HDB5 →
D0PRN4	—	0.961	D0PRN4 →
A2ALI5	—	0.959	A2ALI5 →
Q6UWI2	—	0.957	Q6UWI2 →
Q3TZW0	—	0.957	Q3TZW0 →
A1XQY3	—	0.956	A1XQY3 →
Q6PAL1	—	0.956	Q6PAL1 →
Q60522	—	0.955	Q60522 →
Q9NZ53	—	0.954	Q9NZ53 →
Q4V9H3	—	0.954	Q4V9H3 →
O60279	—	0.954	O60279 →
Q0IIY7	—	0.954	Q0IIY7 →
Q8C985	—	0.953	Q8C985 →
B5X216	—	0.953	B5X216 →
Q8NBI3	—	0.953	Q8NBI3 →
P0C8S2	—	0.953	P0C8S2 →
B5X1Q3	—	0.953	B5X1Q3 →
Q29435	—	0.952	Q29435 →
P56975	—	0.952	P56975 →
Q923D3	—	0.952	Q923D3 →
Q9UKB5	—	0.952	Q9UKB5 →
Q5RAF8	—	0.952	Q5RAF8 →